Skip to main content
SpringerLink
Log in

Is this a death knell for anti-interleukin-5 therapy in asthma?

  • Clinical Trials Report
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wardlaw AJ, Brightling CE, Green R, et al.: New insights into the relationship between airway inflammation and asthma. Clin Sci (Lond) 2002, 103:201–211.

    Article  CAS  Google Scholar 

  2. Kay AB, Phipps S, Robinson DS: A role for eosinophils in airway remodeling in asthma. Trends Immunol 2004, 25:477–482.

    Article  PubMed  CAS  Google Scholar 

  3. Green RH, Brightling CE, McKenna S, et al.: Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002, 360:1715–1721.

    Article  PubMed  Google Scholar 

  4. O’Byrne P: The demise of anti IL-5 for asthma, or not. Am J Respir Crit Care Med 2007, 176:1059–1061.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Phillip Lieberman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lieberman, P. Is this a death knell for anti-interleukin-5 therapy in asthma?. Curr Allergy Asthma Rep 9, 41–42 (2009). https://doi.org/10.1007/s11882-009-0006-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-009-0006-5

Keywords

Search

Navigation